You may communicate with any of our directors, including the Lead Independent Director and the Audit Committee Chair, by writing to them c/o Margaret M. Madden, Senior Vice President and Corporate Secretary, Chief Governance Counsel at Pfizer Inc., 235 East 42nd Street, New York, New York 10017.

Alternatively, you may communicate via email with any of our directors through our Lead Independent Director(link sends e-mail) or members of our Audit Committee through our Audit Committee Chair(link sends e-mail), (both of whom are independent, non-employee directors of the Company).

The Corporate Governance committee looks at the level of qualifications and expertise in various disciplines represented by the current board to determine if there is a need to further enhance the composition of the board to fulfill a specific need. In reviewing candidates recommended by shareholders, the board has established guidelines in the Criteria for Board Membership

Learn more about Criteria for Board Membership.

Visit the Corporate Governance Committee

Proposals for Inclusion in Our 2022 Proxy Materials

Proposal in our 2022 proxy materials for presentation at our 2022 Annual Meeting of Shareholders, then the proposal must be received at our principal executive offices at 235 East 42nd Street, New York, New York 10017, Attention: Corporate Secretary, by November 12, 2021. All proposals must comply with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the Exchange Act).

Director Nominations for Inclusion in our 2022 Proxy Materials (Proxy Access)

Any shareholder considering a proxy access nomination should carefully review our By-laws, which are available at https://investors.pfizer.com/corporate-governance/default.aspx. Under our proxy access by-law, if a shareholder (or a group of up to 20 shareholders) who has owned at least 3% of our shares for at least three years and has complied with the other requirements in our By- laws wants us to include director nominees (up to the greater of two nominees or 20% of the Board) in our 2022 proxy materials for election at our 2022 Annual Meeting of Shareholders, then the nominations must be received by us at our principal executive offices at 235 East 42nd Street, New York, New York 10017, Attention: Corporate Secretary, not earlier than October 13, 2021 and not later than November 12, 2021.

Other Proposals or Nominations to be Brought before Our 2022 Annual Meeting

Any shareholder considering introducing a nomination or other item of business should carefully review the procedures set forth in our By- laws, which are available at https://investors.pfizer.com/corporate-governance/default.aspx. These procedures provide that, among other things, a nomination or the introduction of an item of business at an Annual Meeting of Shareholders must be submitted in writing to our Corporate Secretary at our principal executive offices at 235 East 42nd Street, New York, New York 10017.

We must receive written notice of your intention to nominate a Director or to propose an item of business at our 2022 Annual Meeting according to this schedule:

If the 2022 Annual Meeting is to be held within 25 days before or after the anniversary of the date of this year’s Annual Meeting (April 22, 2021), then Pfizer must receive your notice not less than 90 days nor more than 120 days in advance of the anniversary of the 2021 Annual Meeting. If the 2022 Annual Meeting is to be held on a date not within 25 days before or after such anniversary, then Pfizer must receive it no later than 10 days following the first to occur of:

• the date on which notice of the date of the 2022 Annual Meeting is mailed; or
• the date public disclosure of the date of the 2022 Annual Meeting is made.

Our Annual Meeting of Shareholders is generally held on the fourth Thursday of April. Assuming that our 2022 Annual Meeting is held on schedule, to be "timely" within the meaning of Rule 14a-4(c) under the Exchange Act, we must receive written notice of your intention to introduce a nomination or other item of business at that Meeting between December 23, 2021 and January 22, 2022.

For any other meeting, the nomination or item of business must be received by the 10th day following the date on which public disclosure of the date of the meeting is made.

Upon written request, we will provide, without charge, a copy of our By-laws. Requests should be directed to our principal executive offices at 235 East 42nd Street, New York, New York 10017, Attention: Corporate Secretary.

View Pfizer's annual meeting voting results

Yes, Pfizer maintains a comprehensive compliance program that is designed to detect and respond to policy violations and support legal and ethical conduct throughout the Company. The compliance program is structured in accordance with "Compliance Program Guidance for Pharmaceutical Manufacturers" developed by the United States Department of Health and Human Services, Office of Inspector General and includes the following elements:

• Written Policies and Procedures
• Compliance Officer and Compliance Committees
• Effective Training and Education
• Effective Lines of Communication
• Internal Monitoring and Auditing
• Enforcement Through Discipline Pursuant to Published Guidelines
• Prompt Response and Corrective Action for Detected Problems

The compliance program is overseen and managed by the Compliance Division, which is responsible for helping to develop and implement policies, procedures, and practices to ensure compliance with laws, regulations, and government agreements, as well as investigating violations of law or Pfizer policy. The Compliance Division is led by the Chief Compliance and Risk Officer who reports directly to Pfizer's Chief Executive Officer.

Pfizer's tiered Compliance Committee structure promotes leadership oversight of the compliance program through the Executive Compliance Committee, the North America Compliance Committee, and various business unit and divisional committees.

Additional compliance support is provided by groups and individuals throughout the Company in areas such as legal, safety and monitoring, corporate audit, Human Resources, finance, corporate governance, policy, and other functions.

The CEO's compensation is set by the Compensation Committee and approved by the Board. His actual levels of compensation are adjusted up or down depending on Company and individual performance.

• Annual bonus opportunity ranges from 0% to 200% based on the achievement of pre-set financial goals for the Company for revenue, adjusted diluted earnings per share, and cash flow from operations, as well as his individual goals which support his imperatives for building value, ie, being a leader in science and innovation; continuing to use our financial and commercial strength to enhance competitiveness; earning respect from society; and creating a culture of confidence and trust
• 75% of his long-term equity awards are earned based on relative and absolute total shareholder return. Performance Share Awards (representing 25% of his long-term incentive value) are earned based on Pfizer's relative total shareholder return vs its pharmaceutical peers over a 3-year performance period. Total Shareholder Return Units (representing 50% of his long-term incentive value) are earned based on Pfizer's absolute total shareholder return over 5- and 7-year performance periods

Pfizer's compensation philosophy, which is set by the Compensation Committee, is to align each executive's compensation with Pfizer's short-term and long-term performance and to provide the compensation and incentives needed to attract, motivate, and retain key executives who are crucial to Pfizer's long-term success.

The Global Performance Plan ("GPP"), our annual incentive program, is funded based on Pfizer's performance on 3 financial metrics: total revenue, adjusted diluted earnings per share, and cash flow from operations. The GPP pool is not funded unless performance exceeds a threshold level of performance. Individual awards are earned based on the available earned pool, Business Unit/Function performance, and the achievement of annual performance objectives for the individual.

Our annual long-term incentive awards are aligned with the interests of our shareholders because they deliver value based on absolute and relative shareholder return, encourage stock ownership, and promote retention of key talent.

A significant portion of the total compensation opportunity for each of our executives (including the Named Executive Officers, or "NEOs") is directly related to Pfizer's stock price performance and to other performance factors that measure our progress against the goals of our strategic and operating plans, as well as our performance against that of our pharmaceutical peer group.

* Operating income as the PSA performance measure is based on Pfizer’s Non-GAAP Adjusted Operating Income stated at budgeted foreign exchange rates and is further refined to exclude other unbudgeted or non-recurring items.

Federal law prohibits corporations from contributing directly to candidates running for federal office. The federal contribution ban applies not only to monetary support, but also covers use of corporate resources, such as stationary, fax machines, etc. For this reason, Pfizer's corporate policy prohibits Colleagues from using any vcorporate resources, including Pfizer corporate funds, to support or oppose a candidate seeking federal office.

Pfizer's policy allows for the use of corporate funds in state and local jurisdictions that permit corporate contributions directly to candidates.

Pfizer actively lobbies the US Congress and state legislatures on a number of important public policy issues such as intellectual property, trade, taxes, and public health issues. A complete list of federal issues lobbied by Pfizer in the US can be found in the public disclosure (link is external) sections of the US House and Senate websites. We fully comply with regulations by reporting all federal lobbying in quarterly disclosure reports to Congress.

Effective policies help create an environment in which innovation is encouraged, engaging in public policy debates is part of our responsibility. Please click here for more information.

The Company's relationships with its shareholders and other stakeholders are a critical part of our corporate governance profile, and we recognize the value of taking our investor's views into account. Among other things, engagement helps us to understand the larger context and impact of our operations, and learn about expectations for our performance, assess emerging issues that may affect our business or other aspects of our operations, and shape corporate and governance policies. Over the years, this collaborative approach has helped us to identify mutual perspectives and goals and has resulted in, amongst other things, strengthening our executive compensation program and disclosures.